The Physiological Role of Nesfatien-1 And Its Relationship to Minerals in Patients with Osteoporosis

Abstract

Osteoporosis (OP) is a disease that affects the skeletal system, characterized by decreased bone density (BMD). This study aimed to estimate the level of nesfatin, minerals, and vitamin D3 in osteoporosis patients and to monitor and study the association of nesfatin with patient variability. We collected 150 samples from both sexes (30-65 years old) to achieve this goal. Ninety-three of them were osteoporosis patients. These patients were divided according to the severity of the disease, including osteopenia and osteoporosis. The remaining adults represented a control group, including 57 adults selected for comparison. Nesfatin, calcium (Ca), phosphorus, Ca/P ratio, and magnesium (Mg) were measured. The result indicates that a level of nystatin was highly significantly increased (p≤0.0001) in osteoporosis patients (35.5 ± 11.9 ng/ml) compared to the control group (9.5 ± 3.12 ng/ml). Nystatin was significantly increased (p≤0.0001) in osteoporosis (46.4 ± 4.2 ng/ml), more than in osteopenia (23.7 ± 2.59 ng/ml). There was a significant negative correlation between nesfatine with Mg in OP patients (r = -0.855, p = 0.01) and Vit. D3 (r = -0.846, p = 0.01) in OP. In contrast, there was no significant between nystatin with calcium and phosphorus. We can conclude nesfatin-1 can be considered one of the biochemical indicators of osteoporosis patients, indicating a significant difference between patients and healthy people.